Melfalán Hikma

Melphalan, the active ingredient in Melfalán Hikma, is an alkylating agent presented as a sterile powder for intravenous use. It is employed in the treatment of certain hematologic and solid tumours, particularly in patients requiring high‑dose chemotherapy regimens.

GNH USA supplies Melfalán Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melphalan is an alkylating chemotherapy used in several malignant disease groups. - Multiple myeloma: incorporated into conditioning regimens or combination therapy to eradicate malignant plasma cells. - Ovarian cancer: administered as part of high‑dose chemotherapy protocols for advanced or recurrent disease. - Melanoma: used in isolated limb perfusion or systemic regimens for metastatic lesions.

Melphalan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly observed during treatment. - Myelosuppression: neutropenia, anemia and thrombocytopenia may develop. - Fatigue: persistent tiredness often reported by patients. - Alopecia: reversible hair loss affecting scalp and body hair. - Mucositis: inflammation of the oral and gastrointestinal mucosa. - Diarrhea: loose stools may occur during therapy.

Serious or Rare Side Effects: - Secondary malignancies: risk of therapy‑related cancers such as leukemia. - Severe infection: due to profound neutropenia and immune suppression. - Pulmonary toxicity: interstitial pneumonitis or fibrosis in rare cases. - Renal toxicity: impaired kidney function may develop. - Cardiac arrhythmia: occasional disturbances in heart rhythm. - Anaphylactic reaction: rare but potentially life‑threatening hypersensitivity.

Prior to initiating melphalan therapy, several safety considerations should be addressed. - Renal function: evaluate baseline creatinine and adjust dosing if necessary. - Hematologic monitoring: perform regular complete blood counts to detect myelosuppression. - Pregnancy: avoid use unless the potential benefit justifies the risk to the fetus. - Concomitant myelosuppressive agents: use with caution due to additive bone‑marrow toxicity. - Infection risk: monitor closely for signs of febrile neutropenia and initiate prompt antimicrobial therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Melphalan can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Live vaccines: contraindicated because of immunosuppression. - Strong CYP450 inducers (e.g., rifampin): may reduce melphalan exposure. - Other alkylating agents: additive toxicity to bone marrow and mucosa.

Moderate Interactions (Monitor Closely): - Antiemetics (e.g., ondansetron): may affect nausea control and QT interval. - Nephrotoxic drugs (e.g., cisplatin): increase risk of renal impairment. - Radiation therapy: combined use can enhance tissue damage and fibrosis.